University of Washington School of Medicine: Study Crystallizes Distinct Kidney Benefits of Common Drug
June 25, 2024
June 25, 2024
SEATTLE, Washington, June 25 (TNSres) -- The University of Washington's School of Medicine issued the following news release:
In May, researchers announced the landmark finding that semaglutide, the compound in the common diabetes and weight-loss drugs Ozempic and Wegovy, also effectively reduced risks of kidney and heart complications and death in people with chronic kidney disease and type 2 diabetes.
It was "the biggest win yet of a completed trial for kidney di . . .
In May, researchers announced the landmark finding that semaglutide, the compound in the common diabetes and weight-loss drugs Ozempic and Wegovy, also effectively reduced risks of kidney and heart complications and death in people with chronic kidney disease and type 2 diabetes.
It was "the biggest win yet of a completed trial for kidney di . . .